Phase 1b/2 Evorpacept trial: CD47-binding Ig Fc fusion protein in oncology.

This study evaluates evorpacept in combination with anti-cancer therapies in advanced and metastatic tumors. The trial enrolls patients with HER2+ breast, colorectal, and head and neck cancers in both randomized and dose-escalation cohorts. Sponsored by ALX Oncology across multiple centers, it aims to define the safety and preliminary efficacy of this first-in-human combination approach.